Lutetium-177-PSMA I&T for progressing metastatic castrate-resistant prostate cancer : a single NZ centre experience

Vyas, Madhusudan; Fagan, J.; Lim, R.; Garett, N.

Thumbnail
Share
View fulltext online
Date
2020-10
Citation:
Vyas, M., Fagan, J., Lim, R., & Garett, N. (2020, October). Lutetium-177-PSMA I&T for progressing metastatic castrate-resistant prostate cancer: A single NZ centre experience. Paper presented at the New Zealand Society for Oncology-2020, Auckland, New Zealand.
Permanent link to Research Bank record:
https://hdl.handle.net/10652/5028
Abstract
Objectives Metastatic Castration resistant prostate cancer (mCRPC) Metastatic Castration resistant prostate cancer (mCRPC) and PSMA Various PSMA ligands and radionuclidessuitable for labelling Lu177-PSMA and Mechanism of therapy First reported outcome for Lu177-PSMA-617 Inclusion criteria Exclusion criteria Treatment protocol Response criterion Results: Patient Characteristics Results: Therapy outcomes PSA Response Haematoxicity Quality of Life Outcomes Feedback from patients Image evaluation for therapy responses Limitations Future plan Conclusion References
Keywords:
cancer patients, prostate cancer, theranostics, radionuclide therapy, Lu-177, Lutetium-177, neuroendocrine tumours (NETs), metastatic castration-resistant prostate cancer (mCRPC), mCRPC, New Zealand
ANZSRC Field of Research:
1112 Oncology and Carcinogenesis, 110313 Nuclear Medicine
Copyright Holder:
Authors

Copyright Notice:
All rights reserved
Available Online at:
https://www.nzsoncology.org.nz/programme
Rights:
This digital work is protected by copyright. It may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use. These documents or images may be used for research or private study purposes. Whether they can be used for any other purpose depends upon the Copyright Notice above. You will recognise the author's and publishers rights and give due acknowledgement where appropriate.
Metadata
Show detailed record
This item appears in